A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's ...

Incyte (NASDAQ:INCY – Get Free Report) had its target price dropped by equities research analysts at Morgan Stanley from $69.00 to $65.00 in a research report issued to clients and investors on ...

What Happened? Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Corient Private Wealth LLC lifted its position in Incyte Co. (NASDAQ:INCY – Free Report) by 3.5% during the fourth quarter, according to its most recent 13F filing with the SEC.The institutional ...

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes.

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

Guggenheim lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a neutral rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have $92.00 price ...

(RTTNews) - Incyte Corporation (INCY ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...